Archives of Virology

, Volume 157, Issue 2, pp 259–269 | Cite as

Inhibition of fatty acid synthase by amentoflavone reduces coxsackievirus B3 replication

  • Steffi Wilsky
  • Katharina Sobotta
  • Nadine Wiesener
  • Johanna Pilas
  • Nadine Althof
  • Thomas Munder
  • Peter Wutzler
  • Andreas Henke
Original Article


Coxsackievirus B3 (CVB3) is a human pathogen that causes acute and chronic infections, but an antiviral drug to treat these diseases has not yet been developed for clinical use. Several intracellular pathways are altered to assist viral transcription, RNA replication, and progeny release. Among these, fatty acid synthase (FAS) expression is increased. In order to test the potential of FAS inhibition as an anti-CVB3 strategy, several experiments were performed, including studies on the correlation of CVB3 replication and FAS expression in human Raji cells and an analysis of the time and dose dependence of the antiviral effect of FAS inhibition due to treatment with amentoflavone. The results demonstrate that CVB3 infection induces an up-regulation of FAS expression already at 1 h postinfection (p.i.). Incubation with increasing concentrations of amentoflavone inhibited CVB3 replication significantly up to 8 h p.i. In addition, suppression of p38 MAP kinase activity by treatment with SB239063 decreased FAS expression as well as viral replication. These data provide evidence that FAS inhibition via amentoflavone administration might present a target for anti-CVB3 therapy.


Enhanced Green Fluorescent Protein Orlistat Raji Cell Cerulenin Amentoflavone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors declare that they have no conflict of interest.

Supplementary material

705_2011_1164_MOESM1_ESM.doc (2.8 mb)
Supplementary material 1 (DOC 2833 kb)


  1. 1.
    Gupta S, Markham DW, Drazner MH, Mammen PP (2008) Fulminant myocarditis. Nat Clin Pract Cardiovasc Med 5(11):693–706PubMedCrossRefGoogle Scholar
  2. 2.
    Badorff C, Knowlton KU (2004) Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside. Med Microbiol Immunol 193(2–3):121–126PubMedCrossRefGoogle Scholar
  3. 3.
    Martin U, Nestler M, Munder T, Zell R, Sigusch HH, Henke A (2004) Characterization of coxsackievirus B3-caused apoptosis under in vitro conditions. Med Microbiol Immunol (Berl) 193(2–3):133–139Google Scholar
  4. 4.
    Heim A, Weiss S (2004) Interferons in enteroviral heart disease: modulation of cytokine expression and antiviral activity. Med Microbiol Immunol 193(2–3):149–154PubMedCrossRefGoogle Scholar
  5. 5.
    Klingel K, Sauter M, Bock CT, Szalay G, Schnorr JJ, Kandolf R (2004) Molecular pathology of inflammatory cardiomyopathy. Med Microbiol Immunol 193(2–3):101–107PubMedCrossRefGoogle Scholar
  6. 6.
    Rabenau HF, Richter M, Doerr HW (2010) Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med Microbiol Immunol 199(1):45–51PubMedCrossRefGoogle Scholar
  7. 7.
    Whitton JL, Cornell CT, Feuer R (2005) Host and virus determinants of picornavirus pathogenesis and tropism. Nat Rev Microbiol 3(10):765–776PubMedCrossRefGoogle Scholar
  8. 8.
    Esfandiarei M, McManus BM (2008) Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol 3:127–155PubMedCrossRefGoogle Scholar
  9. 9.
    Vuorinen T, Vainionpaa R, Heino J, Hyypia T (1999) Enterovirus receptors and virus replication in human leukocytes. J Gen Virol 80(Pt 4):921–927PubMedGoogle Scholar
  10. 10.
    Mena I, Perry CM, Harkins S, Rodriguez F, Gebhard J, Whitton JL (1999) The role of B lymphocytes in coxsackievirus B3 infection. Am J Pathol 155(4):1205–1215PubMedCrossRefGoogle Scholar
  11. 11.
    Vuorinen T, Vainionpaa R, Kettinen H, Hyypia T (1994) Coxsackievirus B3 infection in human leukocytes and lymphoid cell lines. Blood 84(3):823–829PubMedGoogle Scholar
  12. 12.
    Matteucci D, Paglianti M, Giangregorio AM, Capobianchi MR, Dianzani F, Bendinelli M (1985) Group B coxsackieviruses readily establish persistent infections in human lymphoid cell lines. J Virol 56(2):651–654PubMedGoogle Scholar
  13. 13.
    Jarasch N, Martin U, Zell R, Wutzler P, Henke A (2007) Influence of pan-caspase inhibitors on coxsackievirus B3-infected CD19+ B lymphocytes. Apoptosis 12:1633–1643PubMedCrossRefGoogle Scholar
  14. 14.
    Klingel K, McManus BM, Kandolf R (1995) Enterovirus-infected immune cells of spleen and lymph nodes in the murine model of chronic myocarditis: a role in pathogenesis? Eur Heart J 16(Suppl O):42–45PubMedGoogle Scholar
  15. 15.
    Anderson DR, Wilson JE, Carthy CM, Yang D, Kandolf R, McManus BM (1996) Direct interactions of coxsackievirus B3 with immune cells in the splenic compartment of mice susceptible or resistant to myocarditis. J Virol 70(7):4632–4645PubMedGoogle Scholar
  16. 16.
    Kandolf R, Sauter M, Aepinus C, Schnorr JJ, Selinka HC, Klingel K (1999) Mechanisms and consequences of enterovirus persistence in cardiac myocytes and cells of the immune system. Virus Res 62(2):149–158PubMedCrossRefGoogle Scholar
  17. 17.
    Magnani JW, Dec GW (2006) Myocarditis: current trends in diagnosis and treatment. Circulation 113(6):876–890PubMedCrossRefGoogle Scholar
  18. 18.
    Henke A, Jarasch N, Wutzler P (2008) Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis. Expert Rev Vaccines 7(10):1557–1567PubMedCrossRefGoogle Scholar
  19. 19.
    Esfandiarei M, Suarez A, Amaral A, Si X, Rahmani M, Dedhar S, McManus BM (2006) Novel role for integrin-linked kinase in modulation of coxsackievirus B3 replication and virus-induced cardiomyocyte injury. Circ Res 99(4):354–361PubMedCrossRefGoogle Scholar
  20. 20.
    Esfandiarei M, Boroomand S, Suarez A, Si X, Rahmani M, McManus B (2007) Coxsackievirus B3 activates nuclear factor kappa B transcription factor via a phosphatidylinositol-3 kinase/protein kinase B-dependent pathway to improve host cell viability. Cell Microbiol 9(10):2358–2371PubMedCrossRefGoogle Scholar
  21. 21.
    Feuer R, Mena I, Pagarigan RR, Hassett DE, Whitton JL (2004) Coxsackievirus replication and the cell cycle: a potential regulatory mechanism for viral persistence/latency. Med Microbiol Immunol 193(2–3):83–90PubMedCrossRefGoogle Scholar
  22. 22.
    Rassmann A, Henke A, Zobawa M, Carlsohn M, Saluz HP, Grabley S, Lottspeich F, Munder T (2006) Proteome alterations in human host cells infected with coxsackievirus B3. J Gen Virol 87(Pt 9):2631–2638PubMedCrossRefGoogle Scholar
  23. 23.
    Li Y, Webster-Cyriaque J, Tomlinson CC, Yohe M, Kenney S (2004) Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression. J Virol 78(8):4197–4206PubMedCrossRefGoogle Scholar
  24. 24.
    Wakil SJ (1989) Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28(11):4523–4530PubMedCrossRefGoogle Scholar
  25. 25.
    Belov GA, Ehrenfeld E (2007) Involvement of cellular membrane traffic proteins in poliovirus replication. Cell Cycle 6(1):36–38PubMedCrossRefGoogle Scholar
  26. 26.
    Kemball CC, Alirezaei M, Flynn CT, Wood MR, Harkins S, Kiosses WB, Whitton JL (2010) Coxsackievirus infection induces autophagy-like vesicles and megaphagosomes in pancreatic acinar cells in vivo. J Virol 84(23):12110–12124PubMedCrossRefGoogle Scholar
  27. 27.
    Van Kuppeveld FJ, Hoenderop JG, Smeets RL, Willems PH, Dijkman HB, Galama JM, Melchers WJ (1997) Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release. EMBO J 16(12):3519–3532PubMedCrossRefGoogle Scholar
  28. 28.
    Lin YM, Anderson H, Flavin MT, Pai YH, Mata-Greenwood E, Pengsuparp T, Pezzuto JM, Schinazi RF, Hughes SH, Chen FC (1997) In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora. J Nat Prod 60(9):884–888PubMedCrossRefGoogle Scholar
  29. 29.
    Lin YM, Flavin MT, Schure R, Chen FC, Sidwell R, Barnard DL, Huffman JH, Kern ER (1999) Antiviral activities of biflavonoids. Planta Med 65(2):120–125PubMedCrossRefGoogle Scholar
  30. 30.
    Ma SC, But PP, Ooi VE, He YH, Lee SH, Lee SF, Lin RC (2001) Antiviral amentoflavone from Selaginella sinensis. Biol Pharm Bull 24(3):311–312PubMedCrossRefGoogle Scholar
  31. 31.
    Lee JS, Lee MS, Oh WK, Sul JY (2009) Fatty acid synthase inhibition by amentoflavone induces apoptosis and antiproliferation in human breast cancer cells. Biol Pharm Bull 32(8):1427–1432PubMedCrossRefGoogle Scholar
  32. 32.
    Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber S (1996) A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J Virol 70(11):7811–7818PubMedGoogle Scholar
  33. 33.
    Slifka MK, Pagarigan R, Mena I, Feuer R, Whitton JL (2001) Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection. J Virol 75(5):2377–2387PubMedCrossRefGoogle Scholar
  34. 34.
    Verstrepen WA, Kuhn S, Kockx MM, Van De Vyvere ME, Mertens AH (2001) Rapid detection of enterovirus RNA in cerebrospinal fluid specimens with a novel single-tube real-time reverse transcription-PCR assay. J Clin Microbiol 39(11):4093–4096PubMedCrossRefGoogle Scholar
  35. 35.
    Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45PubMedCrossRefGoogle Scholar
  36. 36.
    Jarasch-Althof N, Wiesener N, Schmidtke M, Wutzler P, Henke A (2010) Antibody-dependent enhancement of coxsackievirus B3 infection of primary CD19+ B lymphocytes. Viral Immunol 23(4):369–376PubMedCrossRefGoogle Scholar
  37. 37.
    Nissen E, Pauli G, Vollenbroich D (1997) WST-1 assay–a simple colorimetric method for virus titration. In Vitro Cell Dev Biol Anim 33(1):28–29PubMedCrossRefGoogle Scholar
  38. 38.
    Ngamwongsatit P, Banada PP, Panbangred W, Bhunia AK (2008) WST-1-based cell cytotoxicity assay as a substitute for MTT-based assay for rapid detection of toxigenic Bacillus species using CHO cell line. J Microbiol Methods 73(3):211–215PubMedCrossRefGoogle Scholar
  39. 39.
    Dowling S, Cox J, Cenedella RJ (2009) Inhibition of fatty acid synthase by Orlistat accelerates gastric tumor cell apoptosis in culture and increases survival rates in gastric tumor bearing mice in vivo. Lipids 44(6):489–498PubMedCrossRefGoogle Scholar
  40. 40.
    Browne CD, Hindmarsh EJ, Smith JW (2006) Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J 20(12):2027–2035PubMedCrossRefGoogle Scholar
  41. 41.
    Gao F, Yue TL, Shi DW, Christopher TA, Lopez BL, Ohlstein EH, Barone FC, Ma XL (2002) p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc Res 53(2):414–422PubMedCrossRefGoogle Scholar
  42. 42.
    King EM, Holden NS, Gong W, Rider CF, Newton R (2009) Inhibition of NF-kappaB-dependent transcription by MKP-1: transcriptional repression by glucocorticoids occurring via p38 MAPK. J Biol Chem 284(39):26803–26815PubMedCrossRefGoogle Scholar
  43. 43.
    Rassmann A, Henke A, Jarasch N, Lottspeich F, Saluz HP, Munder T (2007) The human fatty acid synthase: a new therapeutic target for coxsackievirus B3-induced diseases? Antiviral Res 76(2):150–158PubMedCrossRefGoogle Scholar
  44. 44.
    Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410(6824):37–40PubMedCrossRefGoogle Scholar
  45. 45.
    Huttunen P, Hyypia T, Vihinen P, Nissinen L, Heino J (1998) Echovirus 1 infection induces both stress- and growth-activated mitogen-activated protein kinase pathways and regulates the transcription of cellular immediate-early genes. Virology 250(1):85–93PubMedCrossRefGoogle Scholar
  46. 46.
    Tung WH, Sun CC, Hsieh HL, Wang SW, Horng JT, Yang CM (2007) EV71 induces VCAM-1 expression via PDGF receptor, PI3-K/Akt, p38 MAPK, JNK and NF-kappaB in vascular smooth muscle cells. Cell Signal 19(10):2127–2137PubMedCrossRefGoogle Scholar
  47. 47.
    Guinea R, Carrasco L (1990) Phospholipid biosynthesis and poliovirus genome replication, two coupled phenomena. EMBO J 9(6):2011–2016PubMedGoogle Scholar
  48. 48.
    Fogg MH, Teterina NL, Ehrenfeld E (2003) Membrane requirements for uridylylation of the poliovirus VPg protein and viral RNA synthesis in vitro. J Virol 77(21):11408–11416PubMedCrossRefGoogle Scholar
  49. 49.
    Feuer R, Mena I, Pagarigan R, Slifka MK, Whitton JL (2002) Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro. J Virol 76(9):4430–4440PubMedCrossRefGoogle Scholar
  50. 50.
    Knowles LM, Axelrod F, Browne CD, Smith JW (2004) A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2. J Biol Chem 279(29):30540–30545PubMedCrossRefGoogle Scholar
  51. 51.
    Guerciolini R (1997) Mode of action of orlistat. Int J Obes Relat Metab Disord 21(Suppl 3):S12–S23PubMedGoogle Scholar
  52. 52.
    Ballinger A, Peikin SR (2002) Orlistat: its current status as an anti-obesity drug. Eur J Pharmacol 440(2–3):109–117PubMedCrossRefGoogle Scholar
  53. 53.
    Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64(6):2070–2075PubMedCrossRefGoogle Scholar
  54. 54.
    Adhikari RP, Novick RP (2005) Subinhibitory cerulenin inhibits staphylococcal exoprotein production by blocking transcription rather than by blocking secretion. Microbiology 151(Pt 9):3059–3069PubMedCrossRefGoogle Scholar
  55. 55.
    Chayakulkeeree M, Rude TH, Toffaletti DL, Perfect JR (2007) Fatty acid synthesis is essential for survival of Cryptococcus neoformans and a potential fungicidal target. Antimicrob Agents Chemother 51(10):3537–3545PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Steffi Wilsky
    • 1
  • Katharina Sobotta
    • 1
  • Nadine Wiesener
    • 1
  • Johanna Pilas
    • 2
  • Nadine Althof
    • 1
  • Thomas Munder
    • 2
  • Peter Wutzler
    • 1
  • Andreas Henke
    • 1
  1. 1.Department of Virology and Antiviral TherapyUniversity Hospital Jena, Friedrich Schiller UniversityJenaGermany
  2. 2.Department of Medical Engineering and BiotechnologyUniversity of Applied Sciences JenaJenaGermany

Personalised recommendations